Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events

A method for detecting acute coronary syndrome in a human subject comprising the steps of:

• obtaining a test sample from the biological fluid of the human subject, wherein the biological fluid is selected from a group comprising blood, serum and plasma;
• analyzing the test sample for amount of Bleomycin detectable iron, wherein the step of analyzing comprises comparing the amount of Bleomycin detectable iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L;
• and
• detecting acute coronary syndrome in the human subject.

A method for predicting adverse cardiac outcomes for a human subject comprising the steps of:

• a) obtaining a first test sample from the biological fluid of a human subject at a first time point, wherein the biological fluid is selected from a group comprising blood, serum and plasma;
• b) analyzing the first test sample for amount of catalytic iron;
• c) detecting acute coronary syndrome in the human subject;
• d) obtaining a second test sample from the biological fluid of the human subject after a predefined time interval from the first time point, the predefined time interval being suitable to observe a consequential variation or increase in the levels of catalytic iron, wherein the biological fluid is selected from a group comprising blood, serum and plasma;
• e) analyzing the second test sample for amount of catalytic iron;
• and
• f) predicting one or more adverse cardiac outcome(s) on the basis of analyzing the second test sample.

A method for treating a human subject suffering from acute coronary syndrome comprising:

• a) obtaining a first test sample from the biological fluid of the human subject at a first time point wherein the biological fluid is selected from a group comprising blood, serum and plasma;
• b) analyzing the first test sample for amount of catalytic iron;
• c) detecting acute coronary syndrome in the human subject;
• d) obtaining a second test sample from the biological fluid of the human subject after a predefined time interval from the first time point, the predefined time interval being suitable to observe a consequential variation or increase in the levels of catalytic iron, wherein the biological fluid is selected from a group comprising whole blood, serum and plasma;
• e) analyzing the second test sample for amount of catalytic iron;
• f) predicting one or more adverse cardiac outcome(s) on the basis of analyzing the second test sample;
• and
• g) administering a therapeutically effective amount of one or more iron chelating agent(s).

A method for differentiating chest pain corresponding to acute coronary syndrome from non-cardiac chest pain in a human subject comprising the steps of:

• obtaining a test sample from the serum of the human subject;
• analyzing the test sample for amount of catalytic iron;
• comparing the amount of catalytic iron with a predetermined amount, wherein the step of analyzing comprises comparing the amount of catalytic iron with a predetermined amount, and wherein the predetermined amount is at least about 0.3 μ mole/L;
• and
• differentiating chest pain corresponding to acute coronary syndrome from non-cardiac chest pain in response to comparing.